Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
Joint Authors
Zuckermann, Andreas
Holdaas, Hallvard
De Simone, Paolo
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-10-11
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality.
The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancers.
In kidney transplantation, evidence from registry studies indicates a lower rate of de novo malignancy under mTOR inhibition, with some potentially supportive data from randomized trials of everolimus.
Case reports and small single-center series have suggested that switch to everolimus may be beneficial following diagnosis of posttransplant malignancy, particularly for Kaposi’s sarcoma and nonmelanoma skin cancer, but prospective studies are lacking.
A systematic review has shown mTOR inhibition to be associated with a significantly lower rate of hepatocellular carcinoma (HCC) recurrence versus standard calcineurin inhibitor therapy.
One meta-analysis has concluded that patients with nontransplant HCC experience a low but significant survival benefit under everolimus monotherapy, so far unconfirmed in a transplant population.
Data are limited in heart transplantation, although observational data and case reports have indicated that introduction of everolimus is helpful in reducing the recurrence of skin cancers.
Overall, it can be concluded that, in certain settings, everolimus appears a promising option to lessen the toll of posttransplant malignancy.
American Psychological Association (APA)
Holdaas, Hallvard& De Simone, Paolo& Zuckermann, Andreas. 2016. Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. Journal of Transplantation،Vol. 2016, no. 2016, pp.1-11.
https://search.emarefa.net/detail/BIM-1110893
Modern Language Association (MLA)
Holdaas, Hallvard…[et al.]. Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. Journal of Transplantation No. 2016 (2016), pp.1-11.
https://search.emarefa.net/detail/BIM-1110893
American Medical Association (AMA)
Holdaas, Hallvard& De Simone, Paolo& Zuckermann, Andreas. Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. Journal of Transplantation. 2016. Vol. 2016, no. 2016, pp.1-11.
https://search.emarefa.net/detail/BIM-1110893
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1110893